TNFAIP8 overexpression: a potential predictor of lymphatic metastatic recurrence in pN0 esophageal squamous cell carcinoma after Ivor Lewis esophagectomy

Z Sun, X Liu, JH Song, Y Cheng, Y Liu, Y Jia… - Tumor Biology, 2016 - Springer
Z Sun, X Liu, JH Song, Y Cheng, Y Liu, Y Jia, SJ Meltzer, Z Wang
Tumor Biology, 2016Springer
Esophageal squamous cell carcinoma (ESCC) has a poor prognosis due to high lymphatic
metastatic recurrence rates after Ivor Lewis esophagectomy. We sought to investigate the
correlation between tumor necrosis factor alpha–induced protein 8 (TNFAIP8) expression
and postoperative lymphatic recurrence in patients with pN0 ESCC. One hundred twenty-
two patients with pN0 ESCC undergoing Ivor Lewis esophagectomy were enrolled in this
study. TNFAIP8 overexpression was found in 73 (59.8%) tumor specimens. The 3-year …
Abstract
Esophageal squamous cell carcinoma (ESCC) has a poor prognosis due to high lymphatic metastatic recurrence rates after Ivor Lewis esophagectomy. We sought to investigate the correlation between tumor necrosis factor alpha–induced protein 8 (TNFAIP8) expression and postoperative lymphatic recurrence in patients with pN0 ESCC. One hundred twenty-two patients with pN0 ESCC undergoing Ivor Lewis esophagectomy were enrolled in this study. TNFAIP8 overexpression was found in 73 (59.8 %) tumor specimens. The 3-year lymphatic metastatic recurrence rate among TNFAIP8-overexpressing patients was significantly higher than in TNFAIP8-negative patients (p = 0.003). Multivariate Cox regression identified TNFAIP8 overexpression as an independent risk factor for lymphatic recurrence (p = 0.048). TNFAIP8 messenger RNA (mRNA) levels were significantly higher in patients with lymphatic recurrence than in patients without tumor recurrence (p = 0.019). Stable silencing of TNFAIP8 expression in ESCC-derived cells (Eca109) reduced proliferation, motility, and invasion and induced apoptosis. In addition, transient silencing of TNFAIP8 expression decreased cell motility and invasion and increased apoptosis in a second ESCC-derived cell line (KYSE150). Taken together, these findings suggest that TNFAIP8 overexpression is a potential biomarker to identify pN0 ESCC patients at higher risk of lymphatic recurrence who may benefit from adjuvant therapy.
Springer
以上显示的是最相近的搜索结果。 查看全部搜索结果